Quantum BioPharma Ltd. (QNTM) Stock Score, Valuation & Financial Research

Quantum BioPharma Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for QNTM

Quantum BioPharma Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 2.66. These figures are a research snapshot, not a buy or sell recommendation.

What Quantum BioPharma Ltd. does

Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Quantum BioPharma operates as a biopharmaceutical company focused on the research and development of drug candidates for neurodegenerative, metabolic, and alcohol misuse disorders. The company generates value through the development of its proprietary pipeline and maintains a portfolio of strategic investments in other biotech entities.

Products and services

  • The company's primary product candidate is Lucid-MS, a patented new chemical entity for the treatment of neurodegenerative disorders. It also develops treatments for alcohol misuse and holds equity interests in entities like Unbuzzd Wellness Inc.

Brands and product families

  • Lucid-MS — Lead patented new chemical entity for neurodegenerative disorders. Source
  • unbuzzd™ — Technology licensed to Unbuzzd Wellness Inc. for alcohol metabolism acceleration. Source

Business relationships and partnerships

  • Unbuzzd Wellness Inc. — A company to which Quantum BioPharma licensed its unbuzzd™ technology; Quantum retains an equity interest in the entity. Source

Business strengths to evaluate

  • Proprietary drug development pipeline including Lucid-MS Source

Business risks and research considerations

  • Developmental stage of drug candidates and uncertainty of clinical trial success Source

Sources: Company research source · unbuzzd™

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

QNTM financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.66
Market capitalization:
17.1M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -24.89M
Free cash flow:
USD -8.38M
Cash:
USD 3.64M
Total debt:
USD 962.16K
EPS:
USD -5.65

What stands out

  • Free cash flow is USD -8.38M, negative for the stored period.
  • The balance sheet shows USD 3.64M of cash versus USD 962.16K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 2.68M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for QNTM

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can QNTM fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is QNTM likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for QNTM to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of QNTM's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research QNTM

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.